Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

REFERENCES

• Schrump D S, Altorki N K, Henscke C L, Carter D, Turrisi A T, Gutierrez M E. Non-small cell lung cancer. Cancer. Principles & Practice, 7th Ed., V T DeVita, S Hellman, S A Rosenberg. Lippincott Williams & Wilkins, Philadelphia 2005; 763–809
   Google Scholar
• Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001; 12(Suppl 1)S57–S62, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Buzdar A U, Ibrahim N K, Francis D, Booser D J, Thomas E S, Theriault R L, Pusztai L, Green M C, Arun B K, Giordano S H, Cristofanillli M, Frye D K, Smith T L, Hunt K K, Singletary S E, Sahin A A, Ewer M S, Buchholz T A, Berry D, Hortobagyi G N. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676–3685, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Demetri G D, von Mehren M, Blanke C D, Van den Abbeele A D, Eisenberg B, Roberts P J, Heinrich M C, Tuveson D A, Singer S, Janicek M, Fletcher J A, Silverman S G, Silberman S L, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker B J, Corless C, Fletcher D, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1–11, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Holbro T, Civenni G, Hynes N E. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99–110, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zaczek A, Brandt B, Bielawski K P. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005; 20: 1005–1015, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Qian X, Karpova T, Sheppard A M, McNally J, Lowy D R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004; 23: 1739–1748, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kawada I, Soejima K, Watanabe H, Nakachi I, Naoki K, Eguchi K, Kawamura M, Kobayashi K, Ishizaka A. Quick screening of EGFR mutation using restriction fraction length polymorphism. J Clin Oncol 2005; 23(Suppl)638s, abstr 7071[CSA]
   Google Scholar
• Nagai Y, Miyazawa Huqun H, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M, Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276–7282, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396–403, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schlemmer B O, Sorensen B S, Overgaard J, Olsen K E, Gjerdrum L M, Nexo E. Quantitative PCR—new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004; 64: 511–522, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumara A, Okumura M, Tanaka S, Kanaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y. EGFR mutation status in Japanese lung cancer patients: Genotyping analysis using LightCycler. Clin Cancer Res 2005; 11: 2924–2929, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Bell D W, Lynch T J, Haserlat S M, Harris P L, Okimoto R A, Brannigan B W, Sgroi D C, Muir B, Riemenschneider M J, Iacona R B, Krebs A D, Johnson D H, Giaccone G, Herbst R S, Manegold C, Fukuoka M, Kris M G, Baselga J, Ochs J S, Haber D A. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081–8092, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gomperts B D, Kramer I M, Tatham P E. Signaling pathways operated by receptor protein tyrosine kinases. Signal Transduction, B D Gomperts, I M Kramer, P E Tatham. Elsevier Academic Press, Amsterdam 2003; 257–282
   Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004; 9: 667–676, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chung M J, Jung S H, Lee B J, Kang M J, Lee D G. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 2004; 54: 10–15, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Sordella R, Bell D W, Haber D A, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163–1167, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson B E, Janne P A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64: 7241–7244, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shao H, Cheng H Y, Cook R G, Tweardy D J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63: 3923–3930, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wang Q, Greene M I. EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 2005; 79: 100–107, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787–2799, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Herbst R S, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Signal Transduction in Cancer, D A Frank. Kluwer Academic Publishers, Boston 2003; 19–72
   Google Scholar
• El-Rayes B F, LoRusso P M. Targeting the epidermal growth factor receptor. Br J Cancer 2004; 91: 418–424, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bleeker W K, Lammerts van Bueren J J, van Ojik H H, Gerritsen A F, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk M A, van de Winkel J G, Parren P W. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699–4707, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005; 23: 3235–3242, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cunningham M P, Essapen S, Thomas H, Green M, Lovell D P, Topham C, Marks C, Modjtahedi H. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005; 27: 317–325, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev 2005; 24: 129–146, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, Kastberg H. A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2005; 23(Suppl)506, abstr 5530[CSA]
   Google Scholar
• Bianco R, Daniele G, Ciardiello F, Tortora G. Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 2005; 6: 275–287, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Fry D W. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res 2003; 284: 131–139, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003; 278: 15435–15440, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Allen L F, Eiseman I A, Fry D W, Lenehan P F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003; 30(5)65–78, Suppl 16[INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Kwak E L, Sordella R, Bell D W, Godin-Heymann N, Okimoto R A, Brannigan B W, Harris P L, Driscoll R, Fidias P, Lynch T J, Rabindran S K, McGinnis J P, Wissner A, Sharma S V, Isselbacher K J, Settleman J, Haber R A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665–7670, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong K K, Tenen D G, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005; 65: 7096–7101, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Traxler P, Allegrini P R, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane H A, McSheehy P, Mestan J, Meyer T, Tang L, Wartmann M, Wood J, Caravatti G. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931–4941, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Natale R, Bodkin D, Govindan R, Sieckman B, Rizvi N, Capo A, Germonpre P, Dimery I, Webster A, Ranson M. A comparison of the antitumor efficacy of ZD6474 and gefitinib (Iressa™) in patients with NSCLC: Results of a randomised, double-blind phase II study. Lung Cancer 2005; 49(Suppl)S37, abstr O-103[CROSSREF], [CSA]
   Google Scholar
• Baselga J, Arteaga C L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445–2459, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shtiegman K, Kochupurakkai B S, Ben-Basat Y, Yarden Y. Epidermal growth factor receptor in cancer: Genetic aberrations and underlying pathways. American Society of Clinical Oncology 2005 Educational Book, M C Perry. American Society of Clinical Oncology, Alexandria, VA 2005; 689–696
   Google Scholar
• Lui V W, Grandis J R. EGFR-mediated cell cycle regulation. Anticancer Res 2002; 22: 1–11, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Thogersen V B, Sorensen B S, Poulsen S S, Orntoft T F, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227–6233, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Salomon D S, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bigner S H, Humphrey P A, Wong A J, Vogelstein B, Mark J, Friedman H S, Bigner D D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50: 8017–8022, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wong A J, Ruppert J M, Bigner S H, Grzeschik C H, Humphrey P A, Bigner D S, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89: 2965–2969, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moscatello D K, Holgado-Madruga M, Godwin A K, Ramirez G, Gunn G, Zoltick P W, Biegel J A, Hayes R L, Wong A J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536–5539, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962–6970, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004; 58: 927–931, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Learn C A, Hartzell T L, Wikstrand C J, Archer G E, Rich J N, Friedman A H, Friedman H S, Bigner D D, Sampson J H. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10: 3216–3224, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mellinghoff I K, Wang M Y, Vivanco I, Haas-Kogan D A, Zhu S, Dia E Q, Lu K V, Yoshimoto K, Huang J H, Chute D J, Riggs B L, Horvath S, Liau L M, Cavenee W K, Rao P N, Beroukhim R, Peck T C, Lee J C, Sellers W R, Stokoe D, Prados M, Cloughesy T F, Sawyers C L, Mischel P S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012–2024, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ushio Y, Tada K, Shiraishi S, Kamiryo T, Shinojima N, Kochi M, Saya H. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 2003; 8: e281–e288, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gilbertson R J, Hill D A, Hernan R, Kocak M, Geyer R, Olson J, Gajjar A, Rush L, Hamilton R L, Finkelstein S D, Pollack I F. ERBB1 is amplified and over-expressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003; 9: 3620–3624, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Crowe D L, Hacia J G, Hsieh C L, Sinha U K, Rice H. Molecular pathology of head and neck cancer. Histol Histopathol 2002; 17: 909–914, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di G E, Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus M H, Muraro R. Frequent over-expression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004; 204: 317–325, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee J W, Soung Y H, Kim S Y, Nam H K, Park W S, Nam S W, Kim M S, Sun D I, Lee Y S, Jang J J, Lee J Y, Yoo N J, Lee S H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879–2882, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bonner J A, Harari P M, Giralt J, Azarnia N, Cohen R B, Raben C, Jones C, Kies M S, Baselga J, Ang K K. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004; 22(Suppl)489s, abstr 5507[CSA]
   Google Scholar
• Harari P M, Giralt J L, Chinnaiyan P, Azarnia N, Molloy P, Cohen R, Raben C. Results of an international phase III trial of radiation +/− cetuximab (Erbitux™) in patients with locoregional advanced head & neck (H&N) cancer. Ann Oncol 2004; 15(Suppl 3)iii13, abstr 46IN[CSA]
   Google Scholar
• Burtness B. Cetuximab and Cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J Clin Oncol 2005; 23: 5440–5442, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Burtness B, Goldwasser M A, Flood W, Mattar B, Forastiere A A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin and cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646–8654, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Harari P M, Huang S. Radiation combined with EGFR signal inhibitors: Head and neck cancer focus. Sem Radiat Oncol 2006; 16: 38–44, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Walch A, Specht K, Braselmann H, Stein H, Siewert J R, Hopt U, Hofler H, Werner M. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 2004; 112: 747–753, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein over-expression and gene amplification of HER-2 and EGFR in colorectal cancers: An immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895–904, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard G F, Ohira M, Hirakawa K, Mori M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005; 11: 1368–1371, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279–286, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Saltz L B, Meropol N J, Loehrer P J, Sr., Needle M N, Kopit J, Mayer R J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–1208, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tabernero J M, Van Cutsem E, Sastre J, Cervantes A, Van Laethem J L, Humblet Y, Soulie P, Corretge S, Mueser M, De Gramont A. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid(FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR) preliminary results. J Clin Oncol 2004; 22(Suppl)200, abstr 3512[CSA]
   Google Scholar
• Tedesco K L, Lockhart A C, Berlin J D. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol 2004; 5: 393–403, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Nygren P, Sorbye H, Osterlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005; 44: 203–217, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Takei N, Suzuki S, Yoneyama H, Hanawa M, Ooi A. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: Protein over-expression, gene amplification and activation of downstream molecules. Mod Pathol 2004; 17: 1497–1505, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Freeman M R, Washecka R, Chung L W. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res 1989; 49: 6221–6225, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti R, Orlando C. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol 1997; 158: 245–247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ge H, Gong X, Tang C K. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002; 98: 357–361, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Panigrahi A R, Pinder S E, Chan S Y, Paish E C, Robertson J F, Ellis I O. The role of PTEN and its signaling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004; 204: 93–100, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cobleigh M A, Vogel C L, Tripathy D, Robert N J, Scholl S, Fehrenbacher L, Wolter J M, Paton V, Shak S, Lieberman G, Slamon D J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, Latre M L, Pahisa J, Velasco M, Fernandez P, Estape J, Ballesta M. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 1996; 74: 1126–1131, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre M L, Escriche C, Estape J, Ballesta A M. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value. Breast Cancer Res Treat 1998; 51: 109–119, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel C L, Cobleigh M A, Tripathy D, Gutheil J C, Harris L N, Fehrenbacher L, Slamon D J, Murphy M, Novotny W F, Buchmore M, Shak S, Stewart S J, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–726, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–2831, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783–792, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward F, Mayne K, Extra J M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265–4274, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M J, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C H, Steger G, Huang C S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter T M, Ruschoff H J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci M S, Gelber R D. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Romond E H, Perez E A, Bryant J, Suman V J, Geyer C E, Jr, Davidson N E, Tan-Chiu E, Martino S, Paik S, Kaufman P A, Swain S M, Pisansky T M, Fehrenbacher L, Kutteh L A, Vogel V G, Visscher D W, Yothers G, Jenkins R B, Brown A M, Dakhil S R, Mamounas E P, Lingle W L, Klein P M, Ingle J N, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schilder R J. Novel strategies: Update on biologic targeted strategies for ovarian cancer. American Society of Clinical Oncology 2005 Educational Book, M C Perry. American Society of Clinical Oncology, Alexandria, VA 2005; 421–427
   Google Scholar
• Gupta A K, Soto D E, Feldman M D, Goldsmith J D, Mick R, Hahn S M, Machtay M, Muschel R J, McKenna W G. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004; 182: 151–162, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hillls K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Coopes L S, Flanagan A M, Knowles M, Leung S Y, Louis D N, Looijenga L H, Mallowicz B, Pierotti M A, The B, Chenevix-Trench G, Weber B L, Yuen S T, Harris G, Goldstraw P, Nicholson A G, Futreal P A, Wooster R, Stratton M R. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525–526, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirsch F R, Langer C J. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004; 31(Suppl 1)75–82, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli G L, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin W A, Crino L, Gazdar A F, Bunn P A, Jr, Hirsch F R. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23: 5007–5018, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch F R, Rossi E, Bartolini S, Ceresoli G L, Bemis L, Haney J, Witta S, Danenberg K, Domenichini Ludovini I, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin W A, Crino L, Bunn P A, Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643–655, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tang J M, He Q Y, Guo R X, Chang X J. Phosphoryalted Akt over-expression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181–191, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Meert A P, Martin B, Delmotte P, Berghmans T, Lafitte J J, Mascaux C, Paesmans M, Steels T, Verdebout M, Sculier J P. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002; 20: 975–981, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirsch F R, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 2005; 17: 118–122, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirsch F R, Varella-Garcia M, McCoy J, West H, Xavier A C, Gumerlock P, Bunn P A, Jr, Franklin W A, Crowley J, Gandara D R. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838–6845, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997; 15: 2858–2865, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Onn A, Correa A M, Gilcrease M, Isobe T, Massarelli E, Bucana C D, O'Reilly M S, Hong W K, Fidler I J, Putnam J B, Herbst R S. Synchronous over-expression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10: 136–143, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Slebos R J, Boot A J, Evers S G, Mooi W J, Wagenaar S S, van Bodegom P C, Bos J L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738–5741, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5: 1037–1043, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Slebos R J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52(Suppl)2665s–2669s, [INFOTRIEVE], [CSA]
   Google Scholar
• Rodenhuis S, Boerrigter L, Top B, Slebos R J, Mooi W J, van't Veer L, van Zandwijk N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study. J Clin Oncol 1997; 15: 285–291, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Soung Y H, Lee J W, Kim S Y, Seo S H, Park W S, Nam S W, Song S Y, Han J H, Park C K, Lee J Y, Yoo N J, Lee S H. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005; 446: 483–488, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese P P, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857–865, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Eberhard D A, Johnson B E, Amler L C, Goddard A D, Heldens S L, Herbst R S, Ince W L, Janne P A, Januario T, Johnson D H, Klein P, Miller V A, Ostland M A, Ramies D A, Sebisanovic D, Stinson J A, Zhang Y R, Seshagiri S, Hillan K J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900–5909, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Reck M, Heller A, Foernzler D, Moecks J, Ward C, De Rosa F, Sauter G, Brennscheidt U, Gatzemeier U. Molecular markers such as EGFR and kRAS mutations as predictors of sensitivity to erlotinib in patients (pts) with NSCLC: Exploratory subanalyses of TALENT, a phase III trial. Lung Cancer 2005; 49(Suppl 2)S112, abstr PD-155[CROSSREF], [CSA]
   Google Scholar
• Witta S E, Gemmill R M, Hirsch F R, Coldren C D, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan D C, Sugita M, Chan Z, Baron A, Franklin W, Drabkin H A, Girard H A, Gazdar A F, Minna J D, Bunn P A, Jr. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitor in lung cancer cell lines. Cancer Res 2006; 66: 944–950, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirsch F R, Varella-Garcia M, Bunn P A, Jr, Di Maria M V, Veve R, Bremmes R M, Baron A E, Zeng C, Franklin W A. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798–3807, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Paez J G, Janne P A, Lee J C, Tracy S, Greulich H, Gabriel S, Herman P, Kaye F J, Lindeman N, Boggon T J, Naoki K, Sasaki H, Fujii Y, Eck M J, Sellers W R, Johnson B E, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yang S H, Mechanic L E, Yang P, Landi M T, Bowman E D, Wampfler J, Meerzaman D, Hong K M, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso N E, Harris C C, Jen J. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2106–2110, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Tatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513–2520, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 23: 2556–2568, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Janne P A, Engelman J A, Johnson B E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227–3234, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93: 355–363, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Honegger A M, Dull T J, Felder S, Van O E, Bellot F, Szapary D, Schmidt A, Ulrich A, Schlessinger J. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987; 51: 199–209, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba I I, Fong K M, Toyooka S, Shimizu N, Fujisawa T, Minna J D, Gazdar A F. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642–1646, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M. HER2 over-expression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005; 5: 4253–4260, [CROSSREF], [CSA]
   Google Scholar
• Engelman J A, Janne P A, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson B E, Cantley L C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102: 3788–3793, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Amann J, Kalyankrishna S, Massion P P, Ohm J E, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim Y H, Pollack J R, Yanagisawa K, Gazdar A, Minna J D, Kurie J M, Carbone D P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65: 226–235, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, Nakawaga K, Tsuruo T, Kohno N, Fukuoka M, Sone S, Nakamura Y. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029–3043, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Janmaat M L, Kruyt F A, Rodriguez J A, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extra-cellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316–2326, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Han S W, Hwang P G, Chung D H, Kim D W, Im S A, Kim Y T, Kim T Y, Heo D S, Bang Y J, Kim N K. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109–115, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Janmaat M L, Rodriguez J A, Gallegos-Ruiz M, Kruyt F A, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006; 118: 209–214, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Cappuzzo F, Magrini E, Ceresoli G L, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties C T, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96: 1133–1141, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Elkind N B, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005; 65: 1770–1777, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• She Q B, Solit D, Basso A, Moasser M M. Resistance to gefitinib in PTEN-null HER-over-expressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340–4346, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bianco R, Shin I, Ritter C A, Yakes F M, Basso A, Rosen N, Tsurutani J, Dennis P A, Mills G B, Arteaga C L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812–2822, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92: 1711–1719, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon T J, Dayaram T, Janne P A, Kocher O, Meyerson M, Johnson B E, Eck M J, Tenen D G, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786–792, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V A, Politi K A, Riely G J, Somwar R, Zakowski M F, Kris M G, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006; 51: 363–368, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yasui H, Shirao K, Yamamoto N, Shimada Y, Yamada Y, Muro K, Hamaguchi T, Boku N, Yoshino T, Saijo N. A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmakokinetics (PK). J Clin Oncol 2005; 23(Suppl)243s, abstr 3209[CSA]
   Google Scholar
• Isobe T, Herbst R S, Onn A. Current management of advanced non-small cell lung cancer: Targeted therapy. Semin Oncol 2005; 32: 315–328, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Gatzemeier U, Rossell R, Ramlau R, Szczesna A, Quoix E, Font A, Jimenez E, Mueser M, Harstrick A. Cetuximab (C225) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 642, abstr 2582[CSA]
   Google Scholar
• Mehta M, Manon R. Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: Combined modality treatment?. Semin Oncol 2005; 32(Suppl 3)S25–S34, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Robert F, Blumenschein R F, Herbst R S, Fossella F V, Tseng J, Saleh M N, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 9089–9096, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004; 72: 257–266, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ready N. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Semin Oncol 2005; 32(Suppl 3)S35–S41, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10: 4607–4613, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin O, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong P P, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–2246, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kris M G, Natale R B, Herbst R S, Lynch T J, Jr, Prager D, Belani C P, Schiller J H, Kelly K, Spiridonidis H, Sandler A, Albain K S, Cella D, Wolf M K, Averbuch S D, Ochs J J, Kaye A C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149–2158, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Veronese M L, Algazy K, Bearn L, Eaby B, Alavi J, Evans T, Stevenson J P, Shults J. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania. Cancer Invest 2005; 23: 296–302, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137–139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cohen M H, Williams G A, Sridhara R, Chen G, McGuinn W D, Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212–1218, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Aoe K, Hiraki A, Murakami T, Maeda T, Umemori Y, Katayama H, Eda R, Takeyama H. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res 2005; 25: 415–418, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Solit D B, She Y, Lobo J, Kris M G, Scher H I, Rosen N, Sirotnak F M. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11: 1983–1989, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee D H, Han J Y, Lee H G, Lee J J, Lee E K, Kim H Y, Kim H K, Hong E K, Lee J S. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11: 3032–3037, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kommareddy A, Coplin M A, Gao F, Behnken D, Romvari E, Read W, Govindan R. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 2004; 45: 221–225, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43: 317–322, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• West H, Franklin W A, Gumerlock P H, Vance R B, Lau D H, McCoy J, Crowley J, Gandara D R. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. J Clin Oncol 2004; 22(Suppl)620s, abstr 7014[CSA]
   Google Scholar
• Akerley W, Maul S, Majer M, Fitzpatrick F. Erlotinib for good prognosis patients with untreated, advanced stage NSCLC. Lung Cancer 2005; 49(Suppl 2)S233, abstr P–442[CSA]
   PubMedGoogle Scholar
• Cadranel J, Debove P, Quoix E, Soria J, Friard S, Peroil M, Souquet P, Vergnenegre A, Morot-Silibot D, Milleron B. Phase II study of gefitinib (IRESSA) administrered as first line treatment in patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC). Lung Cancer 2005; 49(Suppl)S367, abstr P-941[CROSSREF], [CSA]
   Google Scholar
• Lee D, Han J, Lee H G, Lee J J, Lee E K, Kim H Y, Kim H K, Hong E K, Lee J S. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11: 3032–3037, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Reck M, Gatzemeier U. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. Onkologie 2005; 28: 623–627, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Suzuki R, Hasegawa Y, Baba K, Saka H, Saito H, Taniguchi H, Yamamoto M, Matsumoto S, Kato K, Shimokata K. A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(Suppl)640s, abstr 7082[CSA]
   PubMedGoogle Scholar
• D'Addario G, Rauch D, Stupp R, Stahel R, Pless M, Mach N, Rufibach K, Petersen J, Betticher D C. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small cell lung cancer (NSCLC): Preliminary results. A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23(Suppl)652s, abstr 7128[CSA]
   Google Scholar
• Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 2006; 24: 64–69, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, Harris D L, Haserlat S M, Supko J G, Haluska F G, Louis D N, Christiani D C, Settleman J, Haber D A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306–13311, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Huang S F, Liu H P, Li L H, Ku Y C, Fu Y N, Tsai H Y, Chen Y T, Lin Y F, Chang W C, Kou H P, Wu Y C, Chen Y R, Tsai S F. High frequency of epidermal growth factor receptor mutations with complex pattern in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195–8203, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chou T Y, Chiu C H, Li L H, Hsiao C Y, Tzen C Y, Chang K T, Chen Y M, Perng R P, Tsai S F, Tsai C M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750–3757, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba J J, Vieitez J M, Maeztu J, Sanchez J J, Queralt L, Mayo C, Mendez P, Moran T, Taron M. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005; 16: 1081–1086, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Han S W, Kim T Y, Hwang P G, Jeong S, Kim J, Choi I S, Oh D Y, Kim J H, Kim D W, Chung D H, Im S A, Kim Y T, Lee J S, Heo D S, Bang Y J, Kim N K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493–2501, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kiura K, Toyooka S, Aoe M, Tabata M, Hosokawa S, Kozuki T, Date M, Ueoka H, Tanimoto M. Effect of epidermal growth factor receptor gene mutations on adverse events of gefitinib in patients with non-small cell lung cancer. J Clin Oncol 2005; 23(Suppl)644s, abstr 7096[CSA]
   PubMedGoogle Scholar
• Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 2005; 50: 385–391, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Kim K S, Jeong J Y, Kim Y C, Na K J, Kim Y H, Ahn S J, Baek S M, Park C S, Park C M, Kim Y I, Lim S C, Park K O. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005; 11: 2244–2251, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim K, Jeong J, Kim M, Na K, Kim Y, Ahn S, Bom H, Kim S, Park K. Improved survival of gefitinib responsive NSCLC patients and predictors of the response. Lung Cancer 2005; 49(Suppl 2)S371, abstr P-956[CROSSREF], [CSA]
   PubMedGoogle Scholar
• Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuga T, Dobashi K, Minna J D, Nakajima T, Mori M. Clinicopathologic significnce of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 6816–6822, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nederlof P, Boerrigter L, van't Veer L, Baas P, van Zandwijk N. Mutations in the epidermal growth factor receptor (EGFR): Retro- and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib. Lung Cancer 2005; 49(Suppl 3)S111, abstr PD-151[CSA]
   Google Scholar
• Prempree T, Wongpaksa C. EGFR mutations in lung cancers treated by gefitinib in Thailand. Lung Cancer 2005; 49(Suppl)S375, abstr P-971[CROSSREF], [CSA]
   Google Scholar
• Riely G J, Miller V A, Pao W, Zakowski M, Ladanyi M, Heelan R T, Kris M G. Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib. J Clin Oncol 2005; 23(Suppl)641s, abstr 7085[CSA]
   PubMedGoogle Scholar
• Rizvi N A, Pao W, Kris M G, Rusch V, Ladanyi M, Ginex P K, Zakowsi M F, Tyson L B. A prospective study to correlate EGFR mutations with gefitinib response. J Clin Oncol 2005; 23(Suppl)643s, abstr 7091[CSA]
   Google Scholar
• Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez J M, Nishiyama K, Moran T, Ciranqui B, Mate J L, Besse B, Requart N, Perez M, Sanchez J J. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005; 50: 25–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sasaki H, Endo K, Mizuno K, Yano M, Fukai I, Yamakawa Y, Fujii Y. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 2006; 51: 135–136, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M, Yasumoto K. Epidermal growth factor receptor mutations are associated with gefitinib-sensitivity in lung cancer in Japanese. Lung Cancer 2006; 51: 71–77, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara M, Yamomoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829–6837, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate J L, Minnegold C, Ono M, Queralt C, Jahan T, Sanchez J J, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez J M, Moran T. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11: 5878–5885, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Villaflor V, Buckingham L, Gale M, Coon J, Mauer A, Muzzafar T, Kaiser K, Zusag T, Faber L. EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts). Lung Cancer 2005; 49(Suppl 2)S39, abstr O-110[CROSSREF], [CSA]
   Google Scholar
• Wu Y, Lin J, Wang K, Xu C, Zhou Q, Chen G, Yang X, Yang J, Liao R, Huang Y. Chinese EGFR mutations characteristics and sensitivity to gefintinib in lung cancer patients. Lung Cancer 2005; 49(Suppl 2)S114, abstr PD-161[CSA]
   Google Scholar
• Zhang X T, Li L Y, Mu X L, Cui Q C, Chang X Y, Song W, Wang S L, Wang M Z, Zhong W, Zhang L. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005; 16: 1334–1342, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shih J Y, Gow C H, Yu C J, Yang C H, Chang Y L, Tsai M F, Hsu Y C, Chen K Y, Su W P, Yang P C. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non-small cell lung cancer. Int J Cancer 2006; 118: 963–969, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar A F, Shimizu N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167–1173, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst R S, Manegold C, Scagliotti G, Rosell R, Miller V, Natale R B, Schiller J H, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs J S, Averbuch S D, Wolf M K, Rennie P, Fandi A, Johnson D H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial—INTACT 1. J Clin Oncol 2004; 22: 777–784, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Herbst R S, Giaccone G, Schiller J H, Natale R B, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves J A, Wolf M K, Krebs A D, Averbuch S D, Ochs J S, Grous J, Fandi A, Johnson D H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial—INTACT 2. J Clin Oncol 2004; 22: 785–794, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giocanti N, Hennequin C, Rouillard D, Defrance R, Favaudon V. Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer 2004; 91: 2026–2033, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Ready N, Herndon J, Vokes E, Bogart J, Crawford J, Dipetrillo T, Green M. Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. J Clin Oncol 2004; 22(Suppl)632a, abstr 7078[CSA]
   Google Scholar
• Kelly K, Gaspar L E, Chanksy K, Albain K S, Jett J, Ung J J, Crowley J J, Gandara D R. SWOG 0023: A randomized phase III trial of cisplatin/etoposide (PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC). Lung Cancer 2005; 49(Suppl 2)S64, abstr O-192a[CROSSREF], [CSA]
   Google Scholar
• Cella D, Herbst R S, Lynch T J, Prager D, Belani C P, Schiller J H, Heyes A, Ochs J S, Wolf M K, Kay A S, Kris M G, Natale R B. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005; 23: 2946–2954, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Rodrigues P J, Ciuleanu T, Von Pawel J, Thongprasert S, Tan E H, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527–1537, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Robinet G, Berard H, Chouaid C, Kleisbauer J P, Vergnenegre A, Fournel P, Souquet P J, Le Caer H, Belleguic C, Kalla S. A phase II trial of doxetacel alone and in combination with gefitinib as second-line chemotherapy for patients with non-small cell lung cancer: Interim results from Groupe Francais de Pneumo-Cancerologie. Ann Oncol 2004; 15(Suppl 3)iii183, abstr 693P[CSA]
   Google Scholar
• Cufer T, Vrdoljak E. SIGN: A Phase II open-label, randomized study comparing gefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb and IV) non-small-cell lung cancer. Lung Cancer 2005; 49(Suppl 2)S87, abstr PD-070[CROSSREF], [CSA]
   Google Scholar
• Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, Matsumura A, Iuchi K, Haneda H, Suzuki E, Kobayashi Y, Yano M, Fujii Y. EGFR mutations and erbB2 mutations status in Japanese lung cancer patients. Int J Cancer 2006; 118: 180–184, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Miller V A, Kris M G, Shah N, Patel J, Azzoli C, Gomez J, Krug L M, Pao W, Rizvi N, Pizzo B, Tyson L, Venikatramen E, Ben-Porat L, Mernoli N, Zakonski M, Rusch V, Heelan R T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103–1109, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Park J, Park B B, Kim J Y, Lee S H, Lee S I, Kim H Y, Kim J H, Park S H, Lee K E, Park J O, Kim K, Jung C W, Park Y S, Im Y H, Kong W K, Lee M K, Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 4383–4388, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mohamed M K, Ramalingam S, Lin Y, Gooding W, Belani C P. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005; 16: 780–785, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chiu C H, Tsai C M, Chen Y M, Chiang S C, Liou J L, Perng R P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47: 129–138, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Toyooka S, Yatabe Y, Tokumo M, Ichimura K, Asano H, Tomii K, Aoe M, Yanai H, Date H, Mitsudomi T, Shimizu N. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006; 118: 1588–1590, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer—search and destroy. Eur J Cancer 2006; 42: 17–23, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Parra H S, Cavina R, Latteri F, Zucali P A, Campagnoli E, Morenghi E, Grimaldi G C, Roncalli M, Santoro A. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91: 208–212, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli G L, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin W A, Crino L, Bunn P A, Jr, Hirsch F R, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005; 93: 1334–1340, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sequist L, Janne P, Joshi V, Fidias P, Verlander P, Meyerson M, Haber D, Johnson B, Kucherlapati R, Lynch T. The Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard Medical School Partners HealthCare Center for Genetics and genomics experience with clinical testing for somatic EGFR mutations in NSCLC patients. Lung Cancer 2005; 49(Suppl 2)S112, abstr PD-156[CROSSREF], [CSA]
   Google Scholar
• Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I I, Fong K M, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth J A, Herz J, Minna S D, Gazdar A F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–346, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dudek A Z, Kmak K L, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006; 51: 89–96, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pao W, Wang T Y, Riely G J, Miller V A, Pan Q, Ladanyi M, Zakowski M F, Heelan R T, Kris M G, Varmus H E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibamaya T, Matsuo K, Kato K, Kanehiro A, Tamimoto Y, Matsuo K, Ueoka H, Tamimoto M. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: An analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005; 11: 417–424, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Herbst R S. Erlotinib (Tarceva): An update on the clinical trial program. Semin Oncol 2003; 30(Suppl 7)34–46, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Giaccone G, Lechevalier T, Thatcher N, Smit E, Janmaat M, Rodriguez J, Oulid-Aissa D, Soria J C. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 2005; 23(Suppl)638s, abstr 7073[CSA]
   Google Scholar
• Jackman D, Lucca J, Fidias P, Rabin S, Lynch J, Ostler P, Skarin A T, Temel J, Johnson B E, Janne P A. A phase II study of the EGFR tyrosine kinase erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol 2005; 23(Suppl)657s, abstr 7148[CSA]
   PubMedGoogle Scholar
• Felip E, Rojo F, Heller A, Foernzier D, Majo J, Klughammer B, Ramos J, Maacke H, Brennscheidt U, Baselga J, d'Hebron V. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Lung Cancer 2005; 49(Suppl 2)S369, abstr P-949[CROSSREF], [CSA]
   Google Scholar
• Kris M G, Sandler A, Miller V A, Zakowski M F, Pao W, Tsao A, Patel J D, Johnson B, Johnson D H, Carbone D P. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. J Clin Oncol 2005; 23(Suppl)627s, abstr 7029[CSA]
   Google Scholar
• Sandler A, Kris M, Miller V, Carbone D, Pao W, Billheimer D, Tsao A, Paytel J, Johnson D. Phase II trial of erlotinib in patients with bronchioloalveolar carcinoma. Lung Cancer 2005; 49(Suppl 2)S38, abstr O-109[CROSSREF], [CSA]
   Google Scholar
• Tsao M S, Sakurada A, Cutz J C, Zhu C Q, Kamel-Reid S, Squire J, Lorimer J, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Laragde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepheard F A. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133–144, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, von Pawel J, TALENT Study Investigators. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcibatine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(Suppl)619s, abstr 7010[CSA]
   Google Scholar
• Herbst R S, Prager D, Hermann R, Fehrenbacher L, Johnson B E, Sandler A, Kris M G, Tran H T, Klein P, Li X, Ramies D, Johnson D H, Miller V A. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892–5899, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Miller V A, Herbst R, Prager D, Feherbacher L, Hermann R, Hoffman P, Johnson B, Sandler A B, Kris M G, Ramies D. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI.7544) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 2004; 22(Suppl)303, abstr 7061[CSA]
   Google Scholar
• Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins S A, Chinniyan A M, Harari P M. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328–3335, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond L A, Rowinsky E K, Huberman M, Karp D, Rigas J, Clark G M, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238–3247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shepherd F A, Rodrigues P J, Ciuleanu T, Tan E H, Hirsh V, Thongprasert S, Campos D, Maleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar